The present invention relates to a pharmaceutical composition for the prevention and treatment of eye diseases, which comprises a fusion protein in which a tissue permeable peptide and an anti-vascular endothelial cell growth factor preparation are fused as an active ingredient. More specifically, the present invention relates to a tissue permeable peptide A pharmaceutical composition for prevention and treatment of eye diseases comprising as an active ingredient a fusion protein fused with an anti-vascular endothelial cell growth factor (anti-VEGF) agent, a tissue permeable peptide and anti-vascular endothelial growth factor (anti- Converting the recombinant vector comprising the nucleic acid sequence encoding the fusion protein into a host cell； Culturing said cells； And recovering the fusion protein from the cell. The present invention also relates to a method for producing an anti-vascular endothelial cell growth factor preparation having improved resistance and improved efficacy. The composition according to the present invention not only inhibits various growth factors related to neovascularization other than vascular endothelial growth factor but also decreases pericyte coverage and increases efficacy as compared with conventional anti-vascular endothelial growth factor preparations, Of the patients. In addition, drug delivery to the choroidal tissue can be improved by intraocular injection, and thus it can be developed as an eye drop through dose reduction or increase of administration period and improvement of ocular permeability.본 발명은 조직투과성 펩타이드와 항-혈관 내피세포 성장인자 제제가 융합된 융합단백질을 유효성분으로 포함하는 안질환 예방 및 치료용 약학적 조성물에 관한 발명에 대한 것으로, 보다 구체적으로는 조직투과성 펩타이드와 항-혈관 내피세포 성장인자(anti-VEGF) 제제가 융합된 융합단백질을 유효성분으로 포함하는 안질환 예방 및 치료용 약학적 조성물, 조직투과성 펩타이드와 항-혈관 내피세포 성장인자(anti-VEGF) 제제가 융합된 융합단백질을 코딩하는 핵산 서열을 포함하는 재조합 벡터를 숙주세포로 전환시키는 단계； 상기 세포를 배양하는 단계； 및 상기 세포로부터 융합단백질을 회수하는 단계를 포함하는 내성 극복 및 효능이 향상된 항-혈관 내피세포 성장인자 제제를 생산하는 방법에 대한 것이다.본 발명에 따른 조성물은 기존의 항-혈관 내피세포 성장인자 제제와 비교하여 혈관 내
